New Drug-Free PTSD Treatment Reports 68% Remission Rate in Clinical Trial

A new treatment for post-traumatic stress disorder has reported a 68% remission rate in a clinical trial, offering another potential option for people living with PTSD.

Developed by California-based Wave Neuroscience and supported by research from Texas A&M University, the technology uses personalized magnetic brain stimulation instead of medication.

The U.S. Food and Drug Administration cleared the device in June 2026, while an October 23 research announcement highlighted its clinical findings. The development matters in the United States, where PTSD affects both military veterans and civilians.

The device, known as the MeRT System, was tested in a controlled trial involving 158 participants. Researchers found statistically significant improvements in PTSD symptoms compared with a simulated treatment.

The reported remission rate is promising, but the clinical evidence reveals important distinctions about what the treatment has demonstrated.

Inside the Clinical Trial Behind the 68% Figure

Researchers conducted a controlled clinical trial comparing active brain stimulation with a simulated treatment to determine whether the new technology could significantly reduce PTSD symptoms and produce measurable improvements beyond those seen in the comparison group.

According to the FDA’s clinical evidence summary, the randomized, double blind trial assigned 77 participants to active treatment and 81 to a sham treatment group.

Participants underwent approximately 20 to 25 sessions, scheduled five times weekly. The overall treatment completion rate was 84%.

Researchers evaluated symptoms using two established assessments: the PTSD Checklist for DSM 5 (PCL 5) and the Clinician-Administered PTSD Scale for DSM 5 (CAPS 5).

The active treatment group showed an average improvement of 27 points on the PCL-5. Statistically significant differences between treatment groups were also documented on the study’s primary and secondary outcome measures.

A separate analysis found that 68.2% of participants receiving active treatment met remission criteria at a designated follow-up assessment.

That result came from a post hoc analysis of CAPS-5 scores rather than the study’s original primary outcome. It therefore should not be interpreted as a guaranteed recovery rate for future patients.

Why Researchers Are Paying Attention

The findings represent another step in researchers’ efforts to expand PTSD treatment options beyond conventional medications, offering a different approach that uses targeted brain stimulation to help reduce symptoms and improve patient outcomes.

Dr. Erik Won, chief medical officer of Wave Neuroscience, emphasized the results in the October 23 announcement.

“And more importantly, we saw 68% remission in our clinical trial,” Won said.

The company also reported a 52% reduction in PTSD symptoms among participants receiving active treatment. That figure measures improvement within the treated group, not the difference between active and sham treatment.

Dr. Israel Liberzon, a psychiatrist and professor at Texas A&M, highlighted the limited number of medications specifically approved for PTSD.

“Right now, the FDA has approved only two medications for PTSD,” Liberzon said.

Those medications are sertraline and paroxetine. Psychotherapy and other clinical approaches also remain important treatment options.

The FDA cleared MeRT as an adjunctive treatment for adults with PTSD, meaning it is intended to supplement existing care rather than automatically replace it.

Related: 10 Signs Someone May Have Been Through More in Life Than You Realize

How Personalized Brain Stimulation Works

The MeRT System uses measurements of brain activity and other biological signals to determine personalized magnetic stimulation settings, allowing the treatment to be adjusted according to each patient’s recorded biological patterns rather than relying on a standard stimulation frequency.

The system combines electroencephalography (EEG), which measures electrical brain activity, with electrocardiography (ECG) measurements.

Computer-assisted analysis selects a stimulation frequency between 8 and 13 hertz. Magnetic pulses are then delivered through a device positioned against the scalp.

Wave Neuroscience received FDA Breakthrough Device designation in November 2024. The company subsequently submitted its application in early February 2026.

On June 3, 2026, the FDA cleared the MeRT System under submission K260402, finding it substantially equivalent to a legally marketed predicate device.

Although the system personalizes stimulation settings, the clinical trial did not establish whether personalized frequency selection works better than conventional fixed-frequency stimulation.

What the Safety Findings Reveal

The clinical trial reported no serious adverse events among participants, while follow-up assessments showed continued improvements in PTSD symptoms over approximately two to four months, providing additional evidence of the treatment’s effects beyond the initial sessions.

According to the FDA summary, treatment-emergent adverse events occurred at similar rates in the active and sham groups.

Researchers observed continued improvements during follow-up periods extending approximately two to four months. Outcomes beyond that period remain unestablished in the reviewed evidence.

The FDA also reported a statistically significant difference between treatment groups in the post hoc remission analysis. However, the reviewed summary does not provide the corresponding numerical remission percentage for the sham group.

The full peer-reviewed findings had not been publicly released as of October 23.

The study is registered on ClinicalTrials.gov under NCT02990793.

What Comes Next for Patients

The FDA’s clearance of the MeRT System marks a significant regulatory milestone for PTSD treatment, but questions about affordability, insurance coverage, and availability remain important factors in determining how easily patients across the United States can access the technology.

Wave Neuroscience and Texas A&M have discussed efforts to expand treatment availability and improve insurance coverage.

The reviewed information does not establish nationwide treatment pricing, the number of participating clinics, or specific insurance coverage arrangements.

Publishing the full study findings could provide more detail on treatment outcomes and the durability of remission.

For now, MeRT represents another approach to PTSD treatment supported by controlled clinical evidence. Its reported remission rate has attracted attention, but its lasting significance will depend on how clinical results translate into accessible care.

What matters most when evaluating a new PTSD treatment: its reported success rate, how long the results last, or how accessible it is to patients?

More Articles You Might Like:

The post New Drug-Free PTSD Treatment Reports 68% Remission Rate in Clinical Trial appeared first on FODMAP Everyday.